# Breast Implants Market

> Breast Implants Market Research Report: Size, Share, Trend Analysis By Types (Silicone Implants, Saline Implants, Structured Implants), By End Use (Reconstructive Surgery, Cosmetic Surgery, Other Surgical Procedures), By Shape (Round, Anatomical, Teardrop), By Surface Texture (Smooth, Textured, Polyurethane Foam) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast Till 2035

- **Forecast Period:** 2025-2035
- **CAGR:** 5.70%
- **2025:** USD 2.40 Billion
- **2035:** USD 4.18 Billion
- **Key Players:** Allergan Aesthetics (AbbVie), Mentor (Johnson & Johnson), Establishment Labs, Sientra, GC Aesthetics, Polytech Health & Aesthetics, Sebbin, Ideal Implant

**Report ID:** MRFR/HC/4864-HCR · **Pages:** 200 · **Author:** Rahul Gotadki & Kinjoll Dey · **Last Updated:** July 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/breast-implants-market-6325

---

## Market Summary

According to MRFR analysis, the Breast Implants Market Size was valued at USD 3.47 Billion in 2024. The market is projected to grow from USD 3.647 Billion in 2025 to USD 5.997 Billion by 2035, registering a CAGR of 5.1% during the forecast 2026–2035. North America led the market with over 46.11% share, generating around USD 1.6 billion in revenue.
 
The Breast Implants Market is driven by increasing demand for reconstructive and cosmetic procedures, rising awareness of aesthetic enhancement, and advancements in implant technologies, supported by improved surgical techniques and growing acceptance of body image optimization across global populations.
 
According to the World Health Organization (WHO), breast cancer accounts for over 2.3 million new cases annually, driving reconstructive surgeries, while the Institute for Health Metrics and Evaluation (IHME) highlights rising global demand for aesthetic procedures, supporting sustained growth in breast implant adoption.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Rising post-mastectomy reconstruction volumes | +1.3% | Global | Long-term | [2] |
| Social normalization of cosmetic augmentation | +1.1% | NA, Europe, APAC | Medium-term | [10] |
| Nano-textured and cohesive-gel innovation | +0.9% | NA, Europe | Medium-term | [3] |
| Medical-tourism corridor expansion | +0.7% | APAC, South America | Short-term | [8] |
| Expanding insurance and reimbursement mandates | +0.6% | NA, Europe | Long-term | [11] |
| Digital patient-education and telemedicine consultations | +0.4% | Global | Short-term | [12] |
| FDA and EU MDR post-market surveillance reforms | +0.3% | NA, Europe | Long-term | [4] |

### Rising Post-Mastectomy Reconstruction Volumes

According to the International Agency for Research on Cancer [[2]](https://gco.iarc.fr), the global incidence of breast cancer is anticipated to reach 2.6 million new cases each year by 2030. The incidence of immediate reconstruction in the U.S. has risen from 38% in 2017 to a predicted 47% in 2024, largely because of the Women’s Health and Cancer Rights Act, which requires insurers to cover it. A structural demand floor shields much of the Breast Implants Market from discretionary expenditure cycles, with reconstruction being the most resilient long-term driver of the segment.

### Social Normalization of Cosmetic Augmentation

The International Society of Aesthetic Plastic Surgery (ISAPS) reported a 19.3% increase in global aesthetic breast procedures between 2019 and 2023 [[10]](https://isaps.org). Social media platforms and influencer culture have broadened acceptance across age groups and geographies, with patients in the 25–34 cohort now representing the fastest-growing demographic. This attitudinal shift directly supports volume growth in the Breast Implants Market, particularly across premium-tier product lines.

### Nano-Textured and Cohesive-Gel Innovation

Clinical evidence from the Australian Breast Device Registry shows that fifth-generation nano-textured shells reduce capsular contracture incidence to below 3% at five-year follow-up, compared with 8–12% for legacy macro-textured surfaces [[3]](https://journals.lww.com/plasreconsurg). Manufacturers such as Establishment Labs and Polytech Health & Aesthetics have commercialized these surfaces under CE Mark and are pursuing FDA premarket approval pathways — expanding the addressable Breast Implants Market by offering safer long-term outcomes.

### Medical-Tourism Corridor Expansion

In 2024, Thailand, South Korea, and Brazil together performed a projected 420,000 breast-augmentation surgeries on international patients, generating more than USD 1.2 billion in medical-tourism income [[8]](https://medicaltourismassociation.com). These corridors offer procedures at 40-60% lower than North American benchmarks, with norms of JCI-recognized facilities, providing a strong volume driver for the Breast Implants Market in Asia-Pacific and South America.

## Restraints

## Restraints Impact Analysis

Impact estimates below are directional and non-additive. They represent potential dampening effects on the growth trajectory, identified through regulatory filings, clinical literature review, and supply-chain analysis[[13]](https://thelancet.com).

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| BIA-ALCL safety concerns and regulatory recalls | –0.6% | Global | Medium-term | [13] |
| High device and procedural costs | –0.5% | Emerging markets | Long-term | [14] |
| Stringent EU MDR re-certification timelines | –0.4% | Europe | Short-term | [4] |
| Raw-material supply-chain concentration | –0.3% | Global | Medium-term | [15] |
| Patient misinformation and "breast implant illness" discourse | –0.2% | NA, Europe | Short-term | [16] |

### BIA-ALCL Safety Concerns and Regulatory Recalls

In 2019, the Food & Drug Administration (FDA) announced a voluntary recall of Allergan’s Biocell textured implants after the advent of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), and the ramifications of this decision still affect the Breast Implants Market. While the cumulative incidence of BIA-ALCL remained low (estimated 1 in 2,207 to 1 in 86,029 depending on the texture type) [[13]](https://thelancet.com), the incident led to required patient decision checklists and boxed warnings for all implant classes. These approaches have led to longer consultation cycles and a small decrease in elective surgery conversion rates.

### High Device and Procedural Costs

The average total cost of the procedure for implant-based augmentation in North America and Western Europe ranges from USD 5,000 to USD 12,000, which is unaffordable for a considerable proportion of the population in lower-income economies [[14]](https://plasticsurgery.org). This barrier is largely countered by financing choices and medical-tourism alternatives, but affordability limits remain a structural challenge for Breast Implants Market penetration in Sub-Saharan Africa, South Asia, and parts of South America.

### EU MDR Re-Certification Timelines

Stringent European regulatory overhauls are continuously altering product portfolios across the continent. Driven by the breast implants market adapting to the extended EU MDR framework, manufacturers are navigating staggered transitional windows pushing out to December 31, 2027 for high-risk Class III implantable devices, forcing companies to maintain intensive technical files and clinical updates to preserve active CE marks. Several smaller manufacturers have exited the EU market citing prohibitive compliance costs — estimated at EUR 1–3 million per product family — reducing portfolio diversity and concentrating supply among larger players in the Breast Implants Market.

## Opportunities

## Breast Implants Market Opportunities

### Bioabsorbable Scaffold-Implant Hybrid Systems

Next-generation scaffold technologies using poly-L-lactic acid and silk-fibroin matrices are designed to integrate with host tissue over 12–24 months, potentially eliminating long-term foreign-body complications [[17]](https://sciencedirect.com). Companies investing in scaffold-implant hybrids stand to create an entirely new premium tier within the Breast Implants Market, especially for reconstructive indications where biological integration is paramount.

### AI-Powered Surgical Planning and 3D Simulation

Augmented-reality and AI-driven 3D simulation platforms — such as Crisalix and Vectra — are transforming pre-operative consultations, reducing revision rates by helping surgeons and patients align on aesthetic outcomes before entering the operating room [[18]](https://crisalix.com). Licensing and subscription revenue from these planning tools represents a high-margin adjacency for Breast Implants Market participants seeking to diversify beyond device sales.

### Emerging-Market Penetration through Tiered Pricing

Demand in Southeast Asia, the Middle East, and Sub-Saharan Africa remains mostly unfulfilled. Tiered-pricing methods (simplified, cost-optimized implant lines next to premium items) might release an expected incremental yearly revenue of USD 350–500 million by 2032 [[14]](https://plasticsurgery.org). Regulatory harmonization activities under the International Medical Device Regulators Forum (IMDRF) will expedite cross-border approvals for manufacturers targeting various geographies.

### Direct-to-Patient Digital Platforms and Outcome Tracking

Patient-facing digital platforms that combine virtual consultations, financing integration, and long-term outcome tracking are gaining traction. Establishment Labs' Mia platform is creating a real-world evidence dataset that strengthens the company's regulatory and commercial position within the Breast Implants Market [[12]](https://sec.gov).

### Male Chest-Contouring and Gender-Affirming Applications

Gender-affirming top surgery and male pectoral implant demand have grown at an estimated 12–15% annually since 2020 [[19]](https://wpath.org). While still a small share of total volumes, these niche applications are expanding the addressable Breast Implants Market and driving product development for body-specific implant geometries.

## Future Outlook

## Breast Implants Market Future Outlook

### Smart Implants and Connected Health Integration

Sensor-embedded breast implants capable of monitoring intracapsular pressure, temperature, and shell integrity are transitioning from concept to late-stage clinical trials [[17]](https://sciencedirect.com). By 2030, smart implants could enable real-time rupture detection and eliminate the need for routine MRI surveillance — a shift that would reduce lifetime ownership costs by an estimated 25–30% and accelerate adoption in the Breast Implants Market.

### Precision Medicine and Patient-Specific Device Customization

3D-printing and biocompatible material advances will enable patient-specific implant geometries tailored to individual chest-wall anatomy by the early 2030s [[18]](https://crisalix.com). This precision-medicine approach will reduce revision surgery rates and elevate the Breast Implants Market toward a premium-pricing paradigm, with custom devices commanding 30–50% price premiums over standard catalogue offerings.

### Sustainability and Circular-Economy Pressures

Environmental scrutiny of silicone-based medical devices is intensifying. The European Commission's Circular Economy Action Plan is expected to extend extended-producer-responsibility (EPR) requirements to implantable devices by 2028 [[21]](https://ec.europa.eu).

### Regulatory Convergence and Global Harmonization

The IMDRF's ongoing efforts to harmonize medical-device classification and clinical-evidence standards could reduce time-to-market by 12–18 months for implant manufacturers seeking multi-jurisdictional approvals [[22]](https://imdrf.org). For the Breast Implants Market, harmonization would be particularly impactful in Asia-Pacific and South America, where fragmented regulatory landscapes currently delay product launches and limit competition.

## Segment Insights

## Breast Implants Market Segmentation

### By Product Type

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Silicone Implants | 80.3% share (2025) | Preferred natural feel and established safety profile |
| Cohesive Gel Implants | 6.80% CAGR | Form-stable properties; reduced rippling |
| Saline Implants | USD 0.28 Billion (2025) | Adjustable fill volume; lower cost entry point |

Silicone implants dominate the Breast Implants Market because they deliver a tissue-like consistency that patients and surgeons have rated highest in satisfaction surveys across multiple clinical registries [[3]](https://journals.lww.com/plasreconsurg). Fifth-generation cohesive gels — commonly called "gummy bear" implants — are the fastest-growing sub-category within this dimension, earning preference for their shape retention and reduced gel migration risk upon shell breach.

Saline devices maintain a loyal niche, particularly among patients who prioritize the peace of mind that comes with visible deflation in the event of a rupture. Structured saline implants from Ideal Implant have expanded this category by offering an internal architecture that closely mimics silicone aesthetics while preserving the safety advantages of saline fill [[23]](https://idealimplant.com).

### By Shape

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Round | 76.9% share (2025) | Versatile across augmentation and reconstruction |
| Anatomical (Teardrop) | 6.05% CAGR | Natural contour for reconstructive indications |

Round implants remain the workhorse of the Breast Implants Market, favored by surgeons for their predictable behavior in both submuscular and subglandular pocket positions. Anatomical devices are gaining ground in post-mastectomy reconstruction, where a tapered upper pole and fuller lower pole more closely replicate natural breast morphology [[7]](https://plasticsurgery.org).

### By Application

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Cosmetic Surgery | 71.5% share (2025) | Rising social acceptance and self-pay demand |
| Reconstructive Surgery | 5.20% CAGR | Cancer-screening mandates; insurance coverage |

Cosmetic applications generate the majority of Breast Implants Market revenue, driven by self-pay patients across North America, Europe, and Asia-Pacific. Reconstructive demand, while smaller in volume, carries higher ASPs and is less susceptible to economic downturns due to insurance-backed reimbursement pathways [[2]](https://gco.iarc.fr)[[11]](https://congress.gov).

### By End User

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Hospitals | USD 0.68 Billion (2025) | Complex reconstruction; inpatient capabilities |
| Ambulatory Surgical Centers (ASCs) | 40.4% share (2025) | Cost efficiency; outpatient augmentation volume |
| Cosmetology Clinics & Medical Spas | 6.35% CAGR | Premium patient experience; discretionary spending |

ASCs have become the preferred venue for routine augmentation procedures in the Breast Implants Market, offering 20–35% lower facility fees compared with hospital outpatient departments [[14]](https://plasticsurgery.org). Cosmetology clinics and medical spas represent the fastest-growing channel, capitalizing on luxury patient experiences and bundled aesthetic-service offerings.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric | Primary Investment Themes |
| --- | --- | --- |
| North America | 37.7% share (2025) | Insurance-backed reconstruction; premium device mix |
| Europe | 28.5% share (2025) | MDR compliance; oncoplastic surgery specialization |
| Asia-Pacific | 6.93% CAGR (2026–2035) | Medical tourism; rising middle-class spending |
| South America | USD 0.15 Billion (2025) | Brazil-led cosmetic culture; price-sensitive demand |
| Middle East & Africa | 4.8% share (2025) | Medical-tourism hubs (UAE, Saudi Arabia); emerging demand |
| Total | USD 2.40 Billion (2025) | — |

The Breast Implants Market exhibits a clear regional hierarchy, with North America and Europe accounting for nearly two-thirds of global revenue, while Asia-Pacific is closing the gap through rapid volume growth.

### North America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| US | 82.4% of regional share | Largest procedure volume globally; WHRCA mandates |
| Canada | 11.3% of regional share | Provincial health plan coverage for reconstruction |
| Mexico | 6.3% of regional share | Medical-tourism inflows from US patients |

The United States alone accounts for more than 300,000 breast-implant procedures annually, anchored by robust private-insurance coverage for reconstruction and a dense network of board-certified plastic surgeons [[2]](https://gco.iarc.fr)[[7]](https://plasticsurgery.org). Canada's provincial health systems fully cover post-mastectomy procedures, while Mexico is emerging as a cost-effective alternative for elective augmentation, with Tijuana and Guadalajara clinics increasingly serving cross-border patients.

### Europe

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Germany | 5.42% CAGR | Strongest reconstructive surgery infrastructure |
| UK | USD 0.12 Billion (2025) | NHS-funded oncoplastic pathways |
| France | 19.8% of regional share | Historical leadership in implant manufacturing |
| Italy | 14.2% of regional share | Aesthetic procedure culture |
| Spain | 5.15% CAGR | Growing cosmetic tourism from Northern Europe |
| Nordic Countries | 5.8% of regional share | High per-capita healthcare spend |
| Russia | 4.1% of regional share | Growing private-clinic sector |
| Rest of Europe | 11.6% of regional share | EU MDR harmonization driving consolidation |

Europe's Breast Implants Market is shaped by the EU MDR transition, which has consolidated the competitive landscape by raising compliance barriers for smaller manufacturers [[4]](https://fda.gov/medical-devices). France and Germany anchor regional demand through well-established reconstructive-surgery pathways, while Southern European nations are experiencing rapid growth in elective cosmetic procedures.

### Asia-Pacific

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| China | 7.38% CAGR | Expanding private aesthetics market |
| India | 7.52% CAGR | Medical-tourism growth; rising urban incomes |
| Japan | USD 0.09 Billion (2025) | Aging population; reconstruction focus |
| South Korea | 28.4% of regional share | Global leader in cosmetic surgery per capita |
| ASEAN | 6.90% CAGR | Thailand-led medical-tourism corridor |
| Rest of Asia-Pacific | 8.2% of regional share | Australia, New Zealand emerging demand |

Asia-Pacific represents the highest-growth opportunity in the Breast Implants Market. South Korea performs more cosmetic procedures per capita than any other country, while Thailand's medical-tourism sector attracts an estimated 180,000 international breast-augmentation patients annually [[8]](https://medicaltourismassociation.com). China's private aesthetics clinic sector has grown at double-digit rates since 2020, supported by rising consumer confidence and digital patient-acquisition platforms.

### South America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Brazil | 68.5% of regional share | Second-largest cosmetic surgery market globally |
| Argentina | 18.7% of regional share | Growing middle-class demand |
| Rest of South America | 12.8% of regional share | Colombia, Chile expanding clinic networks |

Brazil is the engine of South America's Breast Implants Market, with ISAPS ranking it as the world's second-largest market for aesthetic procedures [[10]](https://isaps.org). The country's Unified Health System (SUS) covers reconstruction for cancer patients, creating a dual-track demand structure spanning both public and private sectors.

### Middle East & Africa

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 5.95% CAGR | Vision 2030 healthcare investment |
| UAE | 33.6% of regional share | Dubai as regional aesthetics hub |
| South Africa | 19.4% of regional share | Largest private healthcare infrastructure on continent |
| Egypt | 5.48% CAGR | Emerging demand in private sector |
| Rest of MEA | 24.8% of regional share | Early-stage market development |

The UAE has positioned Dubai as a premium medical-tourism destination for aesthetic procedures, attracting patients from across the GCC and South Asia. Saudi Arabia's Vision 2030 healthcare expansion is driving new hospital and clinic construction that will expand the Breast Implants Market addressable base in the region [[20]](https://moh.gov.sa).

## Competitive Benchmarking

## Competitive Benchmarking

The Breast Implants Market exhibits moderate concentration, with the top five players commanding an estimated 65–72% of global revenue. The Herfindahl-Hirschman Index (HHI) sits in the 1,200–1,500 range, indicating a competitive but not fragmented market structure. Strategic positioning hinges on clinical-evidence portfolios, regulatory clearance breadth, and surgeon-relationship networks[[24]](https://Various).

| Company | Est. Revenue Share Range | Key Offerings for Breast Implants Market | Strategic Positioning |
| --- | --- | --- | --- |
| Allergan Aesthetics (AbbVie) | ~18–22% | Natrelle Inspira, 410 form-stable | Broadest product portfolio; dominant US share |
| Mentor (Johnson & Johnson) | ~15–19% | MemoryGel, MemoryShape | Strong surgeon-training programs; US co-leader |
| Establishment Labs | ~8–11% | Motiva Ergonomix, Mia connected platform | Innovation-led; digital health ecosystem |
| Sientra | ~5–8% | Opus, AlloX2 | US-only strategy; surgeon-loyalty focus |
| GC Aesthetics | ~5–7% | Eurosilicone, Nagor | European and LATAM market access |
| Polytech Health & Aesthetics | ~4–6% | Polytech Diagon/Mesmo | German engineering positioning; EU MDR compliant |
| Sebbin | ~3–5% | Sebbin Round, Anatomical | French heritage; strong EU and MEA distribution |
| Ideal Implant | ~2–4% | Structured Saline Implant | Unique structured-saline technology |
| Laboratoires Arion | ~2–3% | Arion Hydrogel, Monobloc | Niche European player; hydrogel focus |
| Hans Biomed | ~2–3% | BellaGel | South Korea-based; APAC market specialist |

## Recent News & Developments

## Recent News & Developments

- Establishment Labs (September 2024): Received FDA premarket approval for its Motiva Ergonomix silicone gel implant, marking the first new silicone implant approval in the US in over a decade. This expands the company's addressable Breast Implants Market in North America [[24]](https://Various).

- U.S. FDA (October 2021): Issued updated guidance on breast implant labeling, requiring standardized patient decision checklists and a mandatory "black box" warning — strengthening informed-consent protocols across the Breast Implants Market [[4]](https://fda.gov/medical-devices).

- Polytech Health & Aesthetics (February 2024): Announced a EUR 45 million expansion of its Dieburg, Germany production facility to increase silicone implant output by 30% and address growing Breast Implants Market demand across Europe and the Middle East [[15]](https://polytech-health-aesthetics.com).
- ISAPS (December 2023): Published its 2023 Global Survey, reporting that breast augmentation remained the world's most-performed cosmetic surgical procedure for the fifth consecutive year, reinforcing the long-term demand trajectory of the Breast Implants Market [[10]](https://isaps.org).

## Report Scope

## Breast Implants Market Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | Global Breast Implants Market |
| Study Period | 2021–2035 |
| CAGR (2026–2035) | 5.70% |
| Base Year 2025 | USD 2.40 Billion |
| Forecast 2035 | USD 4.18 Billion |
| Fastest Growing Segment | Cosmetology Clinics & Medical Spas (6.35% CAGR) |
| Fastest Growing Region | Asia-Pacific (6.93% CAGR) |
| Companies Profiled | 10 |
| Valuation Currency | USD Billion |
| CAGR Driver Disclaimer | Driver impacts are directional and non-additive |

## Frequently Asked Questions

**Q: How long do modern breast implants typically last before requiring replacement?**
A: Current-generation silicone gel and saline implants carry an expected device lifespan of 10–20 years, though many patients retain them longer without complications. Manufacturers recommend imaging surveillance every 5–6 years for silent-rupture screening [3].

**Q: What financing options are available for patients seeking elective breast augmentation?**
A: Most major implant manufacturers partner with healthcare lending platforms such as CareCredit and Alphaeon Credit to offer 12–60-month installment plans. Some clinics also provide in-house financing with interest rates ranging from 0% to 14.9% APR [14].

**Q: How does the EU MDR affect implant availability for European patients?**
A: The regulation has reduced the number of CE-marked implant brands. Remaining manufacturers have invested heavily in clinical evaluation reports to meet the new evidentiary standards [4].

**Q: What role does 3D imaging play in pre-operative planning for implant procedures?**
A: Surgeons use volumetric 3D simulation to model post-operative outcomes, improving patient-surgeon alignment and reducing revision rates by an estimated 15–20%. Platforms like Vectra and Crisalix are now standard in high-volume practices [18].

**Q: Are there meaningful differences in complication rates between submuscular and subglandular implant placement?**
A: Submuscular placement is associated with lower capsular contracture rates but higher animation deformity risk. The pre-pectoral (subfascial) approach is gaining popularity as a middle-ground technique with favorable early outcomes [7].

**Q: How are breast implant registries improving post-market surveillance?**
A: National registries in Australia, the UK, and the Netherlands track device-level outcomes across hundreds of thousands of patients, enabling rapid signal detection for complications. Registry data has directly informed regulatory actions including the Biocell recall [13].

**Q: What supply-chain risks should procurement teams consider when sourcing breast implants?**
A: Medical-grade silicone raw material is concentrated among a handful of suppliers, creating single-source vulnerability. Procurement teams should evaluate manufacturers' dual-sourcing strategies and safety-stock commitments when negotiating contracts [9][15].

**Q: What is the current size of the breast implants market?**
A: The breast implants market reached USD 2.40 billion in 2025 and is projected to reach USD 4.18 billion by 2035.

**Q: What is the CAGR of the breast implants market?**
A: The breast implants market is projected to grow at a CAGR of 5.70% during the forecast period 2026–2035.

**Q: Which region leads the breast implants market?**
A: North America holds the largest share at 37.7%, while Asia-Pacific is the fastest-growing region at 6.93% CAGR.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/breast-implants-market-6325*